68-23-5
Chemical Structure
Norethynodrel
Synonym(s): Enidrel; SC-4642; NSC 15432
- CAS. Nr.: 68-23-5
- Formula:C20H26O2
- Molecular Weight:298.42
IUPAC Name: (8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,4,6,7,8,9,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: ICTXHFFSOAJUMG-SLHNCBLASA-N
SMILES: C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(CCC(C4)=O)[C@@]3([H])CC[C@]12C
Biological Activity: Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Norethynodrel | Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wienke Jr E C, Cavazos F, Hall D G, et al. Ultrastructural effects of norethynodrel and mestranol on human endometrial stroma cell[J]. American Journal of Obstetrics and Gynecology, 1969, 103(1): 102-111.
- [2]. KAHN R H, et al. Effect of long-term treatment with Norethynodrel on A/J and C3H/HeJ mice[J]. Endocrinology, 1969, 84(3): 661-668.
- [3]. Freudenthal R I, et al. The effect of norethynodrel, norethindrone and ethynodiol diacetate on hepatic microsomal drug metabolism[J]. Pharmacological Research Communications, 1974, 6(5): 457-468.
- [4]. Fregly M J, et al. Response of heart rate to acute administration of isoproterenol in rats treated chronically with norethynodrel, ethinyl estradiol, and both combined[J]. Endocrinology, 1977, 100(1): 148-154.
Keywords
